Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels


Background and aim: Fatigue is the commonest symptom in primary biliary cirrhosis (PBC), affecting individuals at all stages of disease. The pathogenesis of fatigue in PBC is unknown although rat models suggest a central nervous system (CNS) cause. We examined the hypothesis that a CNS abnormality related to cholestasis, rather than cirrhosis per se, underlies this symptom.

Patients and methods: Fourteen patients with precirrhotic PBC (stage I–II disease), four patients with stage III–IV PBC, and 11 healthy women were studied using cerebral magnetisation contrast imaging and proton magnetic resonance spectroscopy (MRS).

Results: The globus pallidus magnetisation transfer ratio (MTR), a quantifiable tissue characteristic that may be abnormal in the presence of normal magnetic resonance imaging, was significantly reduced in precirrhotic PBC patients compared with healthy controls. These measurements correlated with blood manganese levels and were more abnormal in the more fatigued subjects. There were no differences in MRS measurements between the three study groups, suggesting that the abnormal MTR was not related to hepatic encephalopathy.

Conclusion: This study suggests that impairments in liver function in PBC may adversely affect the brain long before the development of cirrhosis and hepatic encephalopathy, possibly as a result of altered manganese homeostasis within the CNS.

Fatigue is a common, yet highly subjective, complaint among patients with primary biliary cirrhosis (PBC).1 With the advent of screening liver function tests and serological testing, the diagnosis of PBC is usually made early in the course of the natural history of the condition.2 Consequently, early presenting symptoms such as fatigue have assumed greater importance. The prevalence of fatigue in PBC has been reported to be as high as 80%3–5 although these clinic based studies may have been subject to selection bias. A recent geographically based survey, using a well validated fatigue questionnaire, reported significant fatigue in 40% of PBC patients.6 Fatigue is commonly of sufficient severity to significantly impair health related quality of life and, importantly, affects individuals at all stages of disease.3

Despite the prevalence of fatigue in PBC, the current understanding of its aetiology is limited. Although tools have been developed to measure fatigue in PBC,7 very few clinical studies have addressed its pathophysiology. The symptom complex suggests a central nervous system (CNS) mechanism although there are conflicting reports regarding the presence of peripheral neuromuscular impairment.8–10 Studies on bile duct resected rats, using animal models of fatigue assessment, have suggested three possible mechanisms: (1) decreased hypothalamic release of corticotrophin releasing hormone11; (2) abnormal serotonergic neurotransmission12; and (3) increased brain sensitivity to interleukin 1β.13 However, whether these mechanisms are important in humans and how they are related to chronic cholestatic liver disease remains unclear.

We considered that impaired biliary excretion might result in accumulation of substances within the brain, including heavy metals such as manganese which are normally excreted via the biliary route. There is post-mortem evidence for manganese accumulation within the globus pallidus in patients dying with established cirrhosis.14–17 Furthermore, marked hyperintensity of the globus pallidus (GP) on T1 weighted magnetic resonance imaging (MRI) has been reported both in patients with cirrhosis18–20 and in patients with hypermanganesaemia due to occupational exposure,21 biliary atresia,22 and total parenteral nutrition.22 We hypothesised that the fatigue experienced by patients with PBC, in the absence of cirrhosis, may occur as a consequence of increased GP manganese concentrations as a result of impaired biliary excretion. We used a combination of MRI and MR spectroscopy (MRS) to investigate this.

METHODS

Patient groups
Fourteen women (mean age 60 years (range 41–76)) with a definite diagnosis of PBC, based on an antimitochondrial antibody at a titre of ≥1:40 by immunofluorescence and diagnostic liver histology were studied. All had stage I–II disease based on histological assessment of biopsies taken within the preceding year. Four additional women with stage III or IV disease (mean age 48 years (range 39–59)) were also studied. Mean (SD) serum bilirubin and albumin levels were 7.6 (2.5) μmol/l and 39.4 (2.4) g/l, respectively, in stage I–II patients and 18.8 (12.5) μmol/l and 38.0 (2.9) g/l in stage III–IV patients.

Abbreviations: PBC, primary biliary cirrhosis; CNS, central nervous system; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; MTR, magnetisation transfer ratio; GP, globus pallidus; ROI, region of interest; PU, putamen; WM, white matter

See end of article for authors’ affiliations

Correspondence to:
Dr D Forton, Hepatology Section, Faculty of Medicine, Imperial College London, 10th floor GEQM Building, St Mary’s Hospital, South Wharf Rd, London W2 1NY, UK; d.forton@imperial.ac.uk

Accepted for publication 25 June 2003
Eleven healthy women (mean age 47 years (range 38–65)) were recruited from hospital staff to provide control data for MRI and MRS.

Exclusion criteria for the study were a history of any additional liver disease, CNS altering medication, nocturnal pruritus, claustrophobia, and the presence of ferromagnetic prostheses or cardiac pacemakers.

**Patient assessment**

All patients completed the fatigue impact scale, a measure of the impact of fatigue on daily functioning, comprising physical, cognitive, and psychosocial elements, on the day they were studied. These assessment tools have previously been validated for use in PBC.67 All patients gave blood for measurement of manganese concentrations, as well as other metals (copper, iron, mercury, and cadmium).

**Ethics**

Ethics approval was obtained from the ethics committees of the Imperial College School of Medicine (Ref 4047/93) and was in accordance with the 1975 Helsinki Declaration on Human Rights. All subjects provided written informed consent.

**Magnetic resonance**

All subjects were studied with a protocol that included combined cerebral MRI and proton (1H) MRS.

**Magnetic resonance imaging**

We anticipated that conventional T1 weighted imaging might not detect small changes in T1 shortening in this cohort of patients with early liver disease due to PBC. We therefore employed an MR sequence to measure magnetisation transfer ratios (MTRs). The MTR is a quantitative tissue characteristic that reflects the behaviour of normally MR invisible protons bound to macromolecules.21 It can be considered to give enhanced image contrast and may detect brain parenchymal changes that may not be visible using standard MR techniques. Patients were scanned using a birdcage headcoil in a 1.5 Tesla Eclipse MR scanner (Philips Medical Systems Inc., Cleveland, Ohio, USA). An initial spin echo proton density sequence (TR/TE 2000/20 ms) was followed by the MT sequence (TR/TE 2000/20 ms) with an off resonance radiofrequency (RF) pulse (frequency offset = 1000 Hz, peak amplitude = 10 μT, duty cycle = 22%). These values were selected to optimise the MT effect within energy constraints.

Regions of interest (ROIs) were selected bilaterally in the GP, head of caudate, putamen (PU), thalamus, and frontal white matter (WM). Signal intensity measures were obtained from ROIs in both hemispheres and a mean value was calculated. The MTR was calculated using the following formula:

$$\text{MTR} = 1 - \frac{S_{IRF}}{S_0}$$

where $S_{IRF}$ is the signal intensity in the image employing the off resonance RF pulse and $S_0$ is the signal intensity in the initial proton density image. In order to control for inter-examination system variability, MTR results were expressed as indices normalised to the frontal white matter (ROI – WM)/(ROI + WM) and putamen (ROI – PU)/(ROI + PU) in each patient.

**1H Magnetic resonance spectroscopy**

1H MRS is a technique that generates metabolic information and has been used by our group and others to study both the pathophysiology of hepatic encephalopathy and the neuro-psychological symptoms of chronic hepatitis C infection.24–29 We utilised 1H MRS in this study to exclude the presence of hepatic encephalopathy and to investigate whether there are any fatigue associated 1H MRS features in patients with PBC that may mirror our findings in patients with precirrhotic hepatitis C infection. Two 8 cm³ sized voxels were positioned in the basal ganglia and in the white matter at the level of the centrum semiovale. Single voxel 1H MRS examinations were performed using an automated PRESS sequence (TR 1500 ms, TE 135 ms, and 128 acquisitions).22 In each case, MR spectra were analysed by a single observer who was blinded to the clinical status of the patients. Peak areas were measured for choline, creatinine, and N-acetylaspartate using Philips proprietary software (Philips Medical Systems Inc.). Peak area ratios for choline/creatinine were then calculated.

**Statistical methods**

Data were checked for normality using the Shapiro-Wilk test. Between group comparisons were made with the Student’s t test or the Mann-Whitney U test, as appropriate. Correlations were tested with Pearson’s correlation. When multiple correlations were tested, a correction factor of four, corresponding to the number of subcortical ROIs, was used. All tests were two tailed. Statistical analyses were performed using SPSS version 10 (SPSS Inc., North Carolina, USA).

**RESULTS**

**Fatigue**

Individual total fatigue impact scores are shown in fig 1: 50% of patients had high total fatigue scores (>67), as defined in a recent geographically based survey from our group,67 and constituted the high fatigue group. In the stage III–IV group, two patients with cirrhosis had fatigue scores >67 whereas two stage III patients had low fatigue scores (<25).

**Blood manganese concentrations**

Individual whole blood manganese and copper concentrations are shown in fig 2. Blood manganese and copper concentrations were elevated above the normal range in 5/18 and 8/18 patients, respectively. Other metal concentrations fell within the normal range. There were significant correlations between blood manganese and copper concentrations and the total fatigue impact score (Mn, r = 0.43, p = 0.04; Cu, r = 0.48, p = 0.02). In order to control for a possible effect of minimal hepatic encephalopathy, we excluded patients with stage III–IV PBC from the analysis. The mean blood manganese concentrations were significantly higher in patients with stage III–IV PBC compared to patients with stage I–II PBC. The mean manganese concentration in patients with stage III–IV PBC was 110 μmol/L (range 52–167 μmol/L) compared with 47 μmol/L (range 25–60 μmol/L) in patients with stage I–II PBC (p = 0.03). Of the 5/18 patients with stage III–IV PBC who had blood manganese above the normal range, 4 had high fatigue scores (75%, p = 0.03). These 4 patients with stage III–IV PBC and high manganese concentrations were also the patients who had high copper concentrations (110 μmol/L). Of the 5/18 patients with stage III–IV PBC who had blood copper above the normal range, 4 had high manganese concentrations (80%, p = 0.03). In stage I–II PBC, blood manganese concentrations were all within the normal range and no patient with stage I–II PBC had high copper concentrations.
Cerebral magnetic resonance studies and fatigue in PBC

Whole blood manganese (Mn) and copper (Cu) concentrations indicate the upper limit of normal for manganese (218.5 nmol/l) and copper (22.9 μmol/l).

Manganese concentration was significantly higher in stage I–II patients with high fatigue levels than those with less fatigue (high fatigue 227.6 (59.6) nmol/l; low fatigue 124.7 (64.2) nmol/l; p = 0.01). There was no significant difference in mean blood copper concentrations between the high and low fatigue groups (high fatigue 26.6 (4.5) μmol/l; low fatigue 22.7 (1.5) μmol/l; NS).

Magnetic resonance imaging

Mean GP MTR in stage I–II PBC patients was significantly reduced compared with healthy controls (table 1). This reduction was restricted to the GP and was not seen in other ROIs when secondary comparisons were made (table 1). Data were also expressed as indices normalised to the WM and PU to control for inter-examination system variation. When normalised to the WM, the GP index was significantly reduced in stage I–II PBC patients (mean (SD) stage I–II PBC −0.074 (0.019); healthy controls −0.056 (0.019); p = 0.03) (fig 3). Again, this pattern was restricted to the GP. The four stage III–IV patients had a greater reduction in the GP/WM index although this did not reach statistical significance (fig 3). There were no statistically significant differences when MTRs were normalised to the PU. We then examined whether there was a relationship between fatigue and the GP MTR indices. In stage I–II patients, the GP/WM and GP/PU MTR indices were significantly reduced in the high fatigue group compared with the low fatigue group (GP/WM high fatigue −0.084 (0.018); low fatigue −0.064 (0.014); p = 0.04; GP/PU high fatigue 0.029 (0.021); low fatigue 0.055 (0.015); p = 0.02) (fig 4). There was a strong and significant negative

### Table 1 Magnetic transfer ratios from the five regions of interest in the study groups

<table>
<thead>
<tr>
<th>Region</th>
<th>Healthy controls (n = 11)</th>
<th>PBC stage I–II (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Globus pallidus</td>
<td>35.05 (1.83)</td>
<td>33.24 (2.02)*</td>
</tr>
<tr>
<td>Thalamus</td>
<td>34.70 (1.61)</td>
<td>34.24 (2.04)</td>
</tr>
<tr>
<td>Putamen</td>
<td>31.59 (2.19)</td>
<td>30.53 (1.44)</td>
</tr>
<tr>
<td>Head of caudate</td>
<td>31.23 (1.50)</td>
<td>30.55 (1.57)</td>
</tr>
<tr>
<td>White matter</td>
<td>39.19 (1.32)</td>
<td>38.51 (1.44)</td>
</tr>
</tbody>
</table>

PBC, primary biliary cirrhosis.

*p = 0.03 compared with healthy controls.

Magnetic transfer ratio (MTR) index normalised to white matter in the three study groups. Patients with stage I–II primary biliary cirrhosis (PBC) had a significantly reduced MTR index compared with healthy controls (*p = 0.03). The MTR index in stage III–IV patients was lower than that in stage I–II patients but this did not reach statistical significance. The boxes represent the interquartile range, which contain 50% of values, and the whiskers extend to the highest and lowest values. The median is represented by a line across the box. Differences were tested with the Kruskal-Wallis test (p = 0.01) and post hoc comparisons were made using the Mann-Whitney U test.

Figure 3

Correlation between the globus pallidus magnetisation transfer ratio (MTR) index normalised to white matter and blood manganese concentration.

Figure 5
correlation between the blood manganese concentration and the GP/PU index ($r = -0.75$, $p = 0.008$) (fig 5). There were no associations between the other ROI indices and the manganese level (table 2). In healthy controls, there was no association between age and MTR indices. However, in stage I–II PBC patients there was a significant correlation between patient age and the GP/PU MTR index ($r = 0.55$, $p = 0.02$).

**1H Magnetic resonance spectroscopy**

There were no differences in the choline/creatine ratios between stage I–II PBC patients and healthy controls from the basal ganglia (mean choline/creatine (SD) stage I–II PBC 1.12 (0.15); healthy controls 1.15 (0.19); $p = 0.68$) or from the white matter (stage I–II PBC 1.22 (0.23); healthy controls 1.30 (0.14); $p = 0.38$).

**DISCUSSION**

Fatigue is a multidimensional complaint that may be influenced by a number of factors, including physical symptoms, and psychological determinants such as mood and personality. It is recognised as an important symptom in patients with chronic fatigue syndrome. The pathophysiological basis of fatigue in PBC is not known although experiments with bile duct resected rats have indicated that alterations in neurotransmission, the hypothalamic-pituitary axis, and/or brain sensitivity to cytokines may explain the observed reduction in locomotor activity in rats, the proposed correlate of human fatigue. There is a need for a physical marker of fatigue in humans with PBC as this symptom is highly subjective and its underlying cause is unclear.

In this study, we observed selectively reduced MTRs in the GP in patients with biopsy proven early (non-cirrhotic) liver disease and propose a pathogenetic role for manganese in the development of fatigue in PBC. There have been numerous reports of increased signal intensity on standard MRI in patients with non-cirrhotic liver disease. One study reported basal ganglia hyperintensity in patients with longstanding portal vein thrombosis, which correlated with serum manganese levels. Skehan et al reported GP hyperintensity on T1 weighted imaging in patients with chronic liver disease, which was more marked in patients with cholestatic disease (PBC and primary sclerosing cholangitis) than autoimmune hepatitis. They postulated that an unidentified metabolic process, unrelated to cirrhosis, hepatic encephalopathy, or portosystemic shunt, was the cause of their findings.

Reduced MTRs may result from pathologies that alter the structural integrity and the relative macromolecular water composition of brain parenchyma, such as multiple sclerosis plaques or hepatic encephalopathy, or from deposition of paramagnetic substances. Magnetic resonance experiments with manganese chloride phantoms have demonstrated a strong inverse linear relationship between manganese concentration and MTR. This property has been exploited for the use of paramagnetic contrast agents such as gadolinium. In this study, there was a strong inverse correlation between whole blood manganese concentration and GP MTR indices, consistent with manganese deposition in the GP as a consequence of high blood levels due to impaired biliary excretion. This is supported by similar MR data in patients with hypermanganesaemia due to occupational exposure, total parenteral nutrition, and cirrhosis. Furthermore, in one study of four cirrhotic patients, pre-mortem pallidal signal hyperintensity on T1 weighted imaging was associated with high post-mortem pallidal manganese concentrations. It is unclear whether MTRs change with age in the normal brain, with two recent studies finding no relationship and a third study reporting reductions after the age of 40 years. We found no association between age and MTR indices in healthy controls but we did find an association in stage I–II patients. A possible explanation for this is that, over time, greater quantities of manganese accumulate in the GP in individuals with a predisposition, such as chronic liver disease. The healthy controls in this study were significantly younger than the patients. This is a limitation of the study but in our view it is unlikely to be an important factor as any age related effect is likely to be very small.

Patients with high levels of fatigue had significantly lower pallidal MTR indices than those with less fatigue. In addition, there appeared to be an association between fatigue and blood manganese levels. The extrapyramidal and psychiatric signs and symptoms that are associated with manganese, occurring as a result of exposure to toxic levels of manganese, are generally more serious and florid than mere fatigue and were not seen in our patients. However, the early stages of low level exposure may be characterised by asthenia, anorexia, apathy, hypersomnia, weariness, and irritability. One might postulate that in PBC, elevation in brain manganese is much smaller and only manifests clinically

---

**Table 2** Associations between the magnetic transfer ratio indices and blood manganese levels. Correlations were tested with Pearson’s correlation coefficient

<table>
<thead>
<tr>
<th>MTR index</th>
<th>Pearson correlation coefficient</th>
<th>p Value</th>
<th>MTR index</th>
<th>Pearson correlation coefficient</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normalised to WM</td>
<td></td>
<td></td>
<td>Normalised to PU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>-0.54</td>
<td>0.196</td>
<td>Globus pallidus</td>
<td>-0.75</td>
<td>0.008</td>
</tr>
<tr>
<td>Head of caudate</td>
<td>-0.11</td>
<td>0.720</td>
<td>Head of caudate</td>
<td>-0.53</td>
<td>0.156</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.09</td>
<td>0.761</td>
<td>Thalamus</td>
<td>-0.25</td>
<td>0.393</td>
</tr>
<tr>
<td>Putamen</td>
<td>0.58</td>
<td>0.087</td>
<td>White matter</td>
<td>-0.58</td>
<td>0.087</td>
</tr>
</tbody>
</table>

MTR, magnetisation transfer ratio; PU, putamen; WM, white matter.
with milder symptoms in individuals who are particularly sensitive.

Manganese is an abundant metal in the environment and is an essential element in humans, functioning as an enzyme cofactor and constituent of metalloenzymes. Its absorption is predominantly through the gastrointestinal tract where it is actively transported by the cationic transporter NRAMP IL. In plasma, 80% of manganese is bound to β2-globulin and albumin but a smaller fraction is bound to transferrin. The absorption and distribution of manganese are competitively inhibited by other cations, particularly iron. The major route of excretion is biliary and this serves as the main homeostatic mechanism. Elevated blood manganese concentrations occur in cholestasis and have also been reported in chronic hepatitis. Brain concentrations of manganese are relatively low and tightly regulated. Manganese is transported across the blood-brain barrier by a combination of facilitated diffusion, active transport of the non-protein bound cation, and transferrin dependent endocytosis in cerebral capillaries. The GP, thalamic nuclei, and substantia nigra contain the highest manganese levels but do not correspond to regions with the highest transferrin receptor density. Rather, regions of high manganese concentration are effluent from regions rich in transferrin receptor density, suggesting that axonal transport of manganese may occur.

The basal ganglia have multiple projections and participate in a number of parallel processes, including cognitive and emotional functions in addition to motor tasks. It has been suggested that any pathology that disrupts the pallido-thalamo-cortical loop may result in reduced motivation, which may in turn be interpreted by an individual as central-type fatigue. Indeed, fatigue is extremely common in Parkinson's disease and may antedate the development of motor symptoms. Patients with bilateral lesions of the basal ganglia, especially the GP, appear apathetic and demotivated in the absence of any motor symptoms. Although this is an attractive explanation of the neural basis of fatigue, it remains hypothetical in the current context. It is also possible that manganese deposition in brain structures may result in loss of neuronal and/or glial function leading to alterations in neurotransmission and intracerebrovascular release.

In this way, a link between our observations and the existing animal data, derived from bile duct resected rats, could be possible.

The variation in the reported prevalence of fatigue in PBC may be due in part to the methods employed to measure fatigue. However, dietary manganese intake and other factors, including genetic factors, which determine absorption and distribution of manganese may explain why only a proportion of PBC patients experience fatigue. Indeed, iron deficiency may contribute to greater blood and tissue manganese levels, although in this study no relationship between blood manganese and iron was seen.

In summary, we observed reductions in the MTR in the GP in patients with stage I-II PBC which were strongly correlated with blood manganese levels. This preliminary observation together with other published data suggests that manganese deposition may occur in the GP in PBC in the absence of marked hepatic fibrosis or cirrhosis. The absence of an abnormality in cerebral MRS in these patients suggests that the reduced MTR is not a consequence of hepatic encephalopathy, which itself would not be expected in patients without cirrhosis. The association between fatigue severity and the pallidal MTR raises the possibility that brain manganese accumulation may be an important mechanism in the genesis of fatigue in patients with PBC. Our conclusions are limited by the size of this study. Further studies are warranted to investigate manganese homeostasis in a larger number of patients with PBC and to determine whether MRT abnormalities resolve in parallel with fatigue after liver transplantation. In addition, the possibility of ameliorating fatigue by dietary manganese restriction or iron supplementation requires further study.

ACKNOWLEDGEMENTS

The work was partly supported by Phillips Medical Systems International (Cleveland, Ohio, USA), the UK Department of Health, and the British Medical Research Council. Dr D Forton was supported by a grant from the European Association for the Study of the Liver. We are also grateful to LiverNorth, the patient support group based in Newcastle, for supporting this study.

Authors’ affiliations

D M Forton, S D Taylor-Robinson, Liver Unit, Faculty of Medicine, St Mary’s Hospital Campus, Imperial College London, London, UK, and Robert Steiner MR Unit, MRC Clinical Sciences Centre, Hammersmith Hospital Campus, Imperial College London, London, UK

H C Thomas, Liver Unit, Faculty of Medicine, St Mary’s Hospital Campus, Imperial College London, London, UK

M Prince, J Goldblatt, M Bassendine, D E J Jones, Centre for Liver Research, University of Newcastle, Newcastle, UK

N Patel, A Oatridge, G Hamilton, J M Allsop, J V Hajnal, Robert Steiner MR Unit, MRC Clinical Sciences Centre, Hammersmith Hospital Campus, Imperial College London, London, UK

REFERENCES


